Qpex Biopharma Funding: $165M Raised, Series A (2018)
Qpex Biopharma is based in Cambridge, MA. It has raised $165M in total funding. Latest round: Series A.
Qpex Biopharma funding overview
Qpex Biopharma is based in Cambridge, MA. Qpex Biopharma has raised $165M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series A announced in January 2018. The round record for Qpex Biopharma runs through 2018; nothing later has been disclosed. Investors on record include New Enterprise Associates, Adams Street Partners, LYZZ Capital, Hatteras Venture Partners, Stanford University Draper Fund, U.S. Biomedical Advanced Research and Development Authority…. 6 distinct backers are named across the disclosed rounds.
Qpex Biopharma at a glance
Total raised
$165M
Latest round
Series A
Latest round date
January 2018
Headquarters
Cambridge, MA
Notable investors
New Enterprise Associates, Adams Street Partners, LYZZ Capital, Hatteras Venture Partners, Stanford University Draper Fund, U.S. Biomedical Advanced Research and Development Authority…
Frequently asked about Qpex Biopharma funding
How much has Qpex Biopharma raised?
Qpex Biopharma has raised $165M in total disclosed funding across the rounds on record.
Who has invested in Qpex Biopharma?
New Enterprise Associates, Adams Street Partners, LYZZ Capital, Hatteras Venture Partners, Stanford University Draper Fund, U.S. Biomedical Advanced Research and Development Authority… are named among the investors backing Qpex Biopharma.
What was the latest Qpex Biopharma funding round?
The most recent disclosed round is a Series A, announced in January 2018.
Where is Qpex Biopharma based?
Qpex Biopharma is based in Cambridge, MA.
When did Qpex Biopharma last raise?
The last disclosed Qpex Biopharma round closed in January 2018 at Series A.
Every Qpex Biopharma figure above comes from filings and announced rounds in the StartupFundraising company database and is revised as new rounds are recorded. The lists below compare companies in Cambridge at a similar stage.
